TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03927859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a mail letter, a phone call and a phone call plus mailed letter
Description: All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a mail letter, a phone call and a phone call plus mailed letter
Description: All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.
Study: NCT03586934

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Ropivicaine nerve block (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: ketorolac injection
Study: NCT03927859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a mail letter, a phone call and a phone call plus mailed letter
Description: All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention.
Study: NCT00938665

Intervention type: DEVICE
Intervention: COGNISION™ System
Description: 30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.

Intervention type: DEVICE
Intervention: COGNISION™ System
Description: 30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
Study: NCT04617119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT device
Description: 10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: daily
Study: NCT03586934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Injectable Product
Description: Acetaminophen injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Injectable Solution
Description: Morphine Patient Controlled Analgesia

Intervention type: DRUG
Group type: OTHER
Intervention: hydrocodone bitartrate and acetaminophen
Description: Norco tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: morphine injection

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone Hydrochloride
Description: oxycodone hydrochloride tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: meloxicam tablet
Study: NCT02756533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring of daily parameters recorded by NIV
Description: Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
Study: NCT00047697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil HCl
Description: Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
Study: NCT04617119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: daily
Study: NCT02982889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIQ865A bupivacaine formulation
Description: single subcutaneous injection in medial calf

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIQ865A bupivacaine formulation
Description: single subcutaneous injection in medial calf

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ865A bupivacaine formulation
Description: single subcutaneous injection in medial calf

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIQ865B bupivacaine formulation
Description: single subcutaneous injection in medial calf

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIQ865B bupivacaine formulation
Description: single subcutaneous injection in medial calf
Study: NCT00047697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo used in placed of Donepezil HCL
Study: NCT03698253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA6)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA6/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (TA7/TA7)
Description: The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
Study: NCT04524377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.~The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain.
Study: NCT01934790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
Study: NCT03482089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoprostatectomy
Description: Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
Study: NCT02982889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ865B bupivacaine formulation
Description: single subcutaneous injection in medial calf

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluent for LIQ865
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent for LIQ865
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent for LIQ865
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine hydrochoride
Description: single subcutaneous injection
Study: NCT01945047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
Study: NCT01581515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element everolimus eluting coronary stent
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime everolimus eluting coronary stent
Description: Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
Study: NCT03166501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanicemine
Description: Three 60 min parenteral infusions over a 5 day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three 60 min parenteral infusions over a 5 day period
Study: NCT00707057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg Extended-Release Tablets
Description: Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Study: NCT01302418

Intervention type: DEVICE
Intervention: artus Influenza A/B RT-PCR Test
Description: The investigational assay, used for detecting the presence of Influenza A/B.
Study: NCT03482089

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiotherapy
Description: Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
Study: NCT00802347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I5NP
Description: Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg
Study: NCT01697800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04214366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion irradiation
Description: 22 x 3 Gy(RBE) Carbon Ions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bimodal irradiation
Description: 25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
Study: NCT03630159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Gene modified autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti PD-1
Study: NCT01030016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Description: 25 mg/day, twice a day for 6 weeks
Study: NCT00848900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity
Description: Adding 1 hour outdoor time into school curricula
Study: NCT01164150

Intervention type: RADIATION
Group type: OTHER
Intervention: 45 Gy/25 fractions
Description: Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 Gy/25 fractions
Description: Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
Study: NCT01688622

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 3months Exercise
Description: training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
Study: NCT00014612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphoscintigraphy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphoscintigraphy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01000974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)
Description: Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Two oral doses in primary epoch at 2 and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Two oral doses in primary epoch at 2 and 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Two oral doses in primary epoch at 2 and 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™
Description: One dose in the booster epoch at 15-18 months of age as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™
Description: One dose in the booster epoch at 15-18 months of age as intramuscular injection
Study: NCT02651025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Program
Description: During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6.
Study: NCT00536653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide and Calcium/ Vitamin D supplementation
Description: Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation
Description: 3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonists (Goserelin acetate)
Description: 3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
Study: NCT01364337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower carbohydrate DASH diet
Description: lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
Study: NCT01299051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Steps to Health
Description: Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~* Face-to-face visit with counselor during Month 1 to set specific health goals.~* Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~* Monthly generic health education materials sent via e-mail.~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps to Health Plus!
Description: The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~* Face-to-face visit with counselor at Month 1~* Meeting with exercise physiologist in Month 2~* Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~* Meeting with exercise physiologist during Month 5~* Quarterly biometric feedback (Months 3, 6, 9, and 12)~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments.
Study: NCT01445041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
Study: NCT02716792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
Study: NCT01289548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischaemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischaemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study: NCT05242302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve transfer
Description: the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve transfer
Description: the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve transfer
Description: the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
Study: NCT01751321

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin, placebo
Description: sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
Study: NCT03975504

Intervention type: DEVICE
Group type: OTHER
Intervention: Low Dose Computed Tomography
Description: LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm

Intervention type: DEVICE
Group type: OTHER
Intervention: artificial intelligence (AI)
Description: AI was performed in high-risk individuals recruitment and lung nodules management

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: autofluorescence imaging (AFI)
Description: AFI applied in screening of centrally located SCC.